Adenocarcinomas News and Research

RSS

apceth begins Agenmestencel-T Phase II clinical trial in gastrointestinal cancer patients

apceth, a global leader in engineered cell therapies, today announced the successful completion of the Phase I and initiation of the Phase II part of its ongoing monocentric Phase I/II clinical trial TREAT-ME 1 with the engineered cell therapeutic product Agenmestencel-T, at the Klinikum Grosshadern in Munich.

27 Mar 2015

BUSM researchers discover genes involved in formation of lung tumors

The lung transcription factor Nkx2-1 is an important gene regulating lung formation and normal respiratory functions after birth. Alterations in the expression of this transcription factor can lead to diseases such as lung interstitial disease, post-natal respiratory distress and lung cancer.

3 Mar 2015

MET amplified in NSCLC irrespective of type, genetic background

A third of non-small-cell lung cancers show low- to high-level amplification of the MET gene, according to a German study, with no significant difference in frequency across different types of cancer and genetic backgrounds.

20 Jan 2015

New guidance recommends use of primary HPV test for cervical cancer screening

About 80 million U.S. women ages 25 to 65 should be screened periodically by their health care providers for cervical cancer. At present, the standard way to do that is a Pap smear alone, or co-testing using both a Pap smear and a human papillomavirus (HPV) test.

8 Jan 2015

Single biopsy site may reveal all lung adenocarcinoma genetic mutations

Genetic sequencing of a single tumour site sample may be adequate for identifying cancer gene mutations in patients with lung andenocarcinoma, research published in Science suggests.

18 Dec 2014

CT screening highly sensitive, specific for lung cancer detection

Low-dose computed tomography screening for lung cancer has high specificity and high sensitivity, with just a small number of interval cancers, finds an interim analysis of the NELSON trial.

19 Nov 2014

Mayo Clinic study finds that chromosomal rearrangements can help trace lineage of lung cancer

A diagnostic test based on chromosomal rearrangements can trace the lineage of lung cancer to determine whether two separate lung cancers in the same patient are independent tumors or a tumor that has spread to another region of the lung, a Mayo Clinic study has found. For patients with multiple tumors, that distinction could mean the difference between early stage cancer that may be cured by surgery and incurable late-stage disease.

12 Nov 2014

Researchers explain interaction between HNRNPA2B1 protein and pancreatic cancer development

Researchers from the University of Barcelona have described an interaction between the protein HNRNPA2B1 and pancreatic cancer development which remained unknown. The study, published in the journal Gastroenterology, has proved in human cancer cell lines that this protein is essential to the correct activity of the oncogenic protein KRAS, related to cancer start and development.

11 Nov 2014

Study addresses the challenge of genomic heterogeneity

Known cancer-driving genomic aberrations in localized lung cancer appear to be so consistently present across tumors that a single biopsy of one region of the tumor is likely to identify most of them, according to a paper published today in Science.

10 Oct 2014

XAGE1 antibody confers survival benefits to lung adenocarcinoma patients

Patients with advanced lung adenocarcinoma who produce the XAGE1 antibody appear to survive twice as long as those who do not produce it, Japanese study data show.

24 Sep 2014

Scientists analyze genetic characteristics of cancers using multiple genomic technology platforms

New research partly led by UC San Francisco-affiliated scientists suggests that one in 10 cancer patients would be more accurately diagnosed if their tumors were defined by cellular and molecular criteria rather than by the tissues in which they originated, and that this information, in turn, could lead to more appropriate treatments.

8 Aug 2014

New vaccine reprograms pancreatic tumors and makes them vulnerable to immunotherapy

Researchers at the Johns Hopkins Kimmel Cancer Center have developed and tested a vaccine that triggered the growth of immune cell nodules within pancreatic tumors, essentially reprogramming these intractable cancers and potentially making them vulnerable to immune-based therapies.

18 Jun 2014

Researchers develop new strategy to personalised medicine in advanced cancer patients

Tumour cells can accumulate hundreds or even thousands of DNA mutations which induce the growth and spread of cancer. The number and pattern of mutations differs according to the type of tumour, even among those that are classified as part of the same type of tumours.

30 Apr 2014

Tau Therapeutics presents data of T-type calcium channel inhibitors in treatment of pancreatic cancer

Tau Therapeutics LLC announced today that its academic collaborator, University of Virginia Professor Todd Bauer, MD, presented data at the 105th Annual Meeting of the American Association for Cancer Research (AACR), the premier cancer research event held in San Diego, California from April 5-9.

11 Apr 2014

Blood sample could diagnose many types of solid cancers

A blood sample could one day be enough to diagnose many types of solid cancers, or to monitor the amount of cancer in a patient's body and responses to treatment. Previous versions of the approach, which relies on monitoring levels of tumor DNA circulating in the blood, have required cumbersome and time-consuming steps to customize it to each patient or have not been sufficiently sensitive.

7 Apr 2014

Lobar offers no survival advantage over sublobar resections in NSCLC

Patients do not survive significantly longer after lobectomy for non-small-cell lung cancer than after wedge resection or segmentectomy, indicate US study results.

31 Mar 2014

Driver mutations found in more than half of adenosquamous lung carcinomas

Analysis of a large cohort of Chinese patients with adenosquamous lung carcinoma has identified known mutant kinases in more than half of the tumours, researchers report in the Journal of Thoracic Oncology.

19 Feb 2014

New study documents frequency of EGFR mutations in lung adenocarcinoma in Asian population

Adenocarcinoma histology, female sex, never-smoking status, and Asian ethnicity have been considered the most important factors associated with EGFR mutations in non-small cell lung cancer and response to EGFR inhibitors. A recent study has found that, within the Asian population, the frequency of EGFR mutations associated with other demographic and clinical characteristics is higher than previously reported, even in patients with a history of smoking, suggesting that mutation testing should be done on a broader basis among Asian patients with advanced adenocarcinoma of the lung.

16 Feb 2014

Study describes new tack in treatment of lung adenocarcinomas

The most common genetic subtype of lung cancer, which has long defied treatment with targeted therapies, has had its growth halted by a combination of two already-in-use drugs in laboratory and animal studies, setting the stage for clinical trials of the drugs in patients, researchers at Dana-Farber Cancer Institute and other scientists report in a new study.

31 Jan 2014

BRAF mutations rare in Japanese NSCLC patients

Research in a Japanese cohort of patients with non-small-cell lung cancer indicates that the frequency of BRAF mutations is low and their presence has limited prognostic significance.

27 Jan 2014